Table 7.

The Effects of Using Pegylated Liposomal Doxorubicin (PLD) for Adjuvant Chemotherapy of Advanced and Metastatic Breast Cancer

Treatment Regimen	Phase of Clinical Study	Number of Enrolled Patients	Results			Ref.
			The Total Effective Rate (%)	Median Progression-Free Survival (Months)	Total Median Survival (Months)
Evaluation of the effect and safety of salvage chemotherapy for treating metastatic breast cancer with PLD (40 mg/m2)+cyclophosphamide (500 mg/m2) and 5-fluorouracil (500 mg/m2) in the presence of paclitaxel.	II	45	41.9	8.2	Up to 36.6	[135]
Adjuvant chemotherapy in patients with advanced HER-2 positive breast cancer by PLD (administered at 40 mg/m2 every four weeks) in combination with lapatinib and trastuzumab.	II	–	4	5.8	23.3	[136]
Comparison of combined PLD (administered at 30 mg/m2 every three weeks) and docetaxel with the separate use of docetaxel.	III	–	25–36	7.0–9.8	–	[137]
Examination of the therapeutic efficacy of PLD (administered at 20 mg/m2 every two weeks) in elderly patients with advanced breast cancer and all patients enrolled were older than 70 years.	–	–	33.3	10.3	–	[138]
Evaluation of the combined regimen of PLD (administered at 40 mg/m2 every four weeks) and navelbine (administered at 25 mg/m2 every four weeks) and its therapeutic efficacy in first-line chemotherapy in elderly patients with metastatic breast cancer.	–	34	50	–	3 of 34	[139]